The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Forecasted Market Value Of The Intravenous Iron Drugs Market Across 2026–2030?
The intravenous iron drugs market has witnessed significant expansion recently. This market is expected to expand from $3.81 billion in 2025 to $4.22 billion in 2026, registering a compound annual growth rate (CAGR) of 10.8%. The observed growth in past periods is linked to the widespread incidence of iron deficiency anemia, the inherent limitations of oral iron absorption, the implementation of anemia management protocols in hospitals, increased utilization in dialysis centers, and the clinical effectiveness of IV iron therapies.
The market size for intravenous iron drugs is anticipated to undergo swift expansion in the coming years. This market is projected to attain a value of $6.34 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.7%. This increase during the forecast period is primarily driven by an escalating burden of chronic diseases, an expanding population of dialysis patients, a rise in cancer-related anemia cases, a preference for quick hemoglobin correction, and the broadening of outpatient infusion services. Significant trends expected during this period include the increased application in managing iron deficiency anemia, a growing acceptance among chronic kidney disease patients, a developing preference over oral iron therapies, the expansion of single-dose iron formulations, and enhanced utilization in oncology and gastroenterology.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp
What Primary Drivers Are Shaping The Development Of The Intravenous Iron Drugs Market?
The increasing prevalence of chronic kidney disease (CKD) is anticipated to stimulate the expansion of the intravenous iron drugs market. CKD is defined as the progressive decline of kidney function over time, hindering the kidneys’ capacity to effectively filter waste products and excess fluids from the blood. This rise in CKD cases stems from the growing rates of diabetes and hypertension, which contribute to kidney damage. Intravenous iron drugs assist chronic kidney disease patients by replenishing iron stores, correcting anemia, and improving hemoglobin levels, thereby enhancing oxygen transport and lessening the reliance on erythropoiesis-stimulating agents. As an illustration, Hamadan University of Medical Sciences, an Iran-based institution, projected in July 2025 that the global figure for newly diagnosed chronic kidney diseases would climb to 25.06 million by 2030. Thus, the escalating incidence of chronic kidney disease (CKD) is a primary catalyst for the growth of the intravenous iron drugs market.
What Segmentation Levels Are Considered In The Intravenous Iron Drugs Market?
The intravenous iron drugs market covered in this report is segmented –
1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types
2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran
2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex
3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose
4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate
What Trends Are Projected To Affect The Intravenous Iron Drugs Market?
Leading firms within the intravenous iron drugs market are concentrating on creating novel treatments, including intravenous (IV) iron replacement therapy, to enhance effectiveness, security, and results for patients. This therapy involves a medical procedure where iron is administered straight into the bloodstream via an intravenous infusion. It addresses iron deficiency and anemia, particularly in individuals unable to tolerate or properly absorb oral iron supplements. As an example, in June 2023, Daiichi Sankyo Company Limited, a pharmaceutical enterprise from Japan renowned for its focus on advanced drug development and health solutions, disclosed that the U.S. Food and Drug Administration (FDA) had granted approval for Injectafer (ferric carboxymaltose injection). This approval was specifically for managing iron deficiency in adult heart failure patients categorized as New York Heart Association class II/III, aiming to boost their exercise capacity. Injectafer stands as a frequently utilized intravenous iron treatment, recognized for its ability to swiftly restore iron levels in individuals who either cannot tolerate or do not respond effectively to oral iron supplements.
Which Leading Firms Are Contributing To The Growth Of The Intravenous Iron Drugs Market?
Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd
Read the full intravenous iron drugs market report here:
https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report
How Does The Intravenous Iron Drugs Market Perform Across Major Global Regions?
North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Intravenous Iron Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp
Browse Through More Reports Similar to the Global Intravenous Iron Drugs Market 2026, By The Business Research Company
Iron Deficiency Injectable Market Report 2026
https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report
Hemochromatosis Iron Overload Disease Treatment Market Report 2026
Intravenous Solutions Market Report 2026
https://www.thebusinessresearchcompany.com/report/intravenous-solutions-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model